HC Wainwright Boosts Zymeworks (NYSE:ZYME) Price Target to $12.00

Zymeworks (NYSE:ZYME) had its price objective raised by HC Wainwright from $10.00 to $12.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a neutral rating on the stock. HC Wainwright also issued estimates for Zymeworks’ Q1 2025 earnings at ($0.47) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.55) EPS and FY2025 earnings at ($2.05) EPS.

Separately, Stifel Nicolaus boosted their price target on shares of Zymeworks from $20.00 to $21.00 and gave the company a buy rating in a research note on Friday, August 2nd.

Zymeworks Stock Down 0.4 %

ZYME stock opened at $12.42 on Wednesday. The company’s fifty day simple moving average is $11.28 and its 200 day simple moving average is $9.93. Zymeworks has a 12-month low of $6.01 and a 12-month high of $13.27. The firm has a market cap of $878.16 million, a price-to-earnings ratio of -6.94 and a beta of 1.19.

Zymeworks (NYSE:ZYME) last released its earnings results on Thursday, August 1st. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. Zymeworks had a negative net margin of 179.42% and a negative return on equity of 21.97%. The company had revenue of $19.24 million for the quarter, compared to the consensus estimate of $23.16 million. During the same quarter in the previous year, the company earned ($0.76) EPS. Research analysts expect that Zymeworks will post -0.85 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Rubric Capital Management LP grew its position in Zymeworks by 31.1% during the fourth quarter. Rubric Capital Management LP now owns 3,475,384 shares of the company’s stock valued at $36,109,000 after buying an additional 823,990 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Zymeworks during the 1st quarter worth approximately $579,000. O Shaughnessy Asset Management LLC grew its holdings in Zymeworks by 51.5% during the first quarter. O Shaughnessy Asset Management LLC now owns 255,497 shares of the company’s stock valued at $2,688,000 after purchasing an additional 86,797 shares during the period. Affinity Asset Advisors LLC bought a new position in Zymeworks during the second quarter valued at $1,626,000. Finally, AlphaMark Advisors LLC purchased a new stake in Zymeworks in the first quarter worth $32,000. Hedge funds and other institutional investors own 92.89% of the company’s stock.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.